Dr. Geoffrey T. Yarranton

• 
  www.gbsventurepartners.com.au/news_display_print.asp?Ne - [Cached Version]
  Published on: 4/28/2008    Last Visited: 9/16/2008  

  "This antibody is another example of the power of Humaneering technology," said Geoffrey Yarranton, KaloBios' Chief Scientific Officer.

• 
  www.gbsventurepartners.com.au/news_display.asp?NewsId=2 - [Cached Version]
  Published on: 3/10/2008    Last Visited: 9/16/2008  

  "Anti-GM-CSF antibody treatment has shown efficacy in animal studies of models of lung inflammation, and we are interested to see if similar pharmacodynamic activity can be reproduced in this patient population," said Geoffrey Y. Yarranton, Ph.D., KaloBios' Chief Scientific Officer.

• 
  sanfrancisco.bizjournals.com/sanfrancisco/stories/2008/ - [Cached Version]
  Published on: 3/31/2008    Last Visited: 3/31/2008  

  Geoffrey Yarranton is chief scientific officer at KaloBios, and Tillman Pearce, M.D., is chief medical officer.

• 
  www.fdanews.com/newsletter/article?issueId=11390&articl - [Cached Version]
  Published on: 3/12/2008    Last Visited: 3/12/2008  

  Geoffrey Yarranton, KaloBios' chief scientific officer, said the treatment has demonstrated efficacy in animal studies.

• 
  www.asiaprnews.com/2006-05-31/kalobios-collaborates-to- - [Cached Version]
  Published on: 10/11/2008    Last Visited: 12/1/2007  

  therapeutics," said Geoffrey Yarranton, PhD, CEO of KaloBios.
  ...
  Geoff YarrantonCEO of KaloBios Pharmaceuticals, Inc.,+1-650-843-1897, ext. 301

• 
  www.allens.com.au/pubs/bt/3aug04/bio05.htm - [Cached Version]
  Published on: 8/3/2004    Last Visited: 3/27/2008  

  Dr. Geoffrey Yarranton, CEO of KaloBios Pharmaceuticals, commented, "Because the function of this protein is well conserved among mammals, we are especially optimistic that the information and first generation antibody developed by the LICR will lead to an effective drug in humans.' KaloBios plans to enter the first generation antibody into human clinical trials by the second half of 2005.

• 
  www.kjscanlon.com/articles/from_principal_investigator_ - [Cached Version]
  Published on: 10/11/2008    Last Visited: 8/29/2008  

  Geoffrey Yarranton, PhD, is a scientist-turned businessman who is now CEO of KaloBios.For Yarranton, experience in industry educated him on business, "A lot of times people try to start companies with limited experience.

• 
  5AM Ventures - In The News - [Cached Version]
  Published on: 1/12/2004    Last Visited: 8/5/2008  

  Our future focus will be on quickly building a clinical pipeline of carefully selected human antibody therapeutics," commented Geoffrey Yarranton, Ph.D. of Celscia.
  ...
  "Geoff and his team from Celscia have extensive experience developing antibody-based drugs.
  ...
  KaloBios' board of directors includes Jim Healy, M.D., Ph.D. of Sofinnova Ventures, Doug Kelly, M.D. of Alloy Ventures, Carin Mueller of 5AM Ventures, Geoff Yarranton, Ph.D., and Mark Alfenito, Ph.D. Investors are Sofinnova Ventures, Alloy Ventures, 5AM Ventures and Singapore BioInnovations Pte Ltd, a wholly owned subsidiary of Singapore Economic Development Board Investments.

• 
  ANZA Technology Network | August 2005 Newsletter - [Cached Version]
  Published on: 8/1/2005    Last Visited: 1/29/2008  

  Geoffrey Yarranton - Ph.D., Chief Executive Officer
  ...
  Geoffrey Yarranton
  ...
  Dr. Yarranton has over 20 years of experience in the biotechnologyindustry both in Europe and the US.He spent 16 years at CelltechTherapeutics in the UK where he led their research activities.Duringthat time he led a 'joint venture' between Celltech and AmericanCyanamid (later Wyeth) that developed the first approved antibody-drugconjugate, Mylotarg.Dr. Yarranton also designed and developed thebacterially-produced PEGylated anti-TNF antibody Fab fragment (CDP870)currently in Phase III studies for the treatment of rheumatoidarthritis.In 1998, Dr. Yarranton joined Coulter Pharmaceutical where heled the team that refiled the BLA for Bexxar, a radioiodinated antibodyfor the treatment of relapsed and refractory Non Hodgkin's Lymphoma.Following the acquisition of Coulter Pharmaceutical by Corixa, Dr.Yarranton became site director of the South San Francisco site and

• 
  BIO.COM: Biotechnology & Pharmaceutical News, Jobs,... - [Cached Version]
  Published on: 5/31/2006    Last Visited: 5/31/2006  

  In turn, we are committed to helping GNF and Novartis make the best possible human antibody therapeutics," said Geoffrey Yarranton, PhD, CEO of KaloBios.

Page:  1 2 3 4 5